Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by grosdavidon May 05, 2020 3:10pm

126 Views

Post# 30989309

RE:RE:Fool me once it's on you...fool me twice ..I'm a dummy

Careful, short term investors and day traders lost confidence.

Don't management did this on purpose to hurt everyone (en themselves as they hold alot of shares).

Ask the longs if they have lost confidence. Its sad to hear yes, but the main focus is Ifenprodil and the clinical trials. Not a F*** PP.

Bullboard Posts

Sony’s Alpha 1 II: A new professional photography standard?